Home    Help    Cart    Login
Get Free Updates on Industry Research and Analysis!


Search all reports:
 Go 


Pharma and Biotech News


Marketing Services
Interested in marketing your information product through us? Email us at helpdesk AT pharma-reports.com

or call 800-304-0345




Topic Suggestion?


 Item Detail
Item Detail
You're Here: Biotech



President Obama’s Plans for the U.S. Healthcare and Pharma Sectors

Select Your Format:
Price: $197.00
Shipping: US:  $50.00 
Non-US  $70.00
QTY:
Print Order form to pay by check
Understanding Obama's Healthcare Reforms
Understanding Obama's Healthcare Reforms
Pharma-Reports

The American Recovery and Reinvestment Act of 2009 is an economic stimulus package enacted by the 111th United States Congress and signed into law by President Barack Obama on February 17, 2009.

The Act specifies that 37% of the package is to be devoted to tax cuts equaling $288 billion and $144 billion or 18% is allocated to state and local fiscal relief (more than 90% of the state aid is going to Medicaid and education). 45% or $357 billion is allocated to federal social programs and federal spending programs.

The unprecedented spending package signed into law by President Barack Obama on February 17th, with $787 billion spending and tax cuts, has major implications for healthcare, including individual providers, with $150 billion in new spending attached.

This report takes a look at President Obama’s plans for the U.S. healthcare and pharma sectors.


Table of Contents



38 pages

Publication Date : May 2009
 Options
Options
Select Your Format:
 Your Price
Your Price
Price: $197.00
Shipping: US:  $50.00 Non-US  $70.00
 QTY: 

Print Order form to pay by check


 Related Items
Related Items
Strategic Alliances in World Pharma and Biotech Markets Strategic Alliances in World Pharma and Biotech Markets

In the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years. Regardless of its size, every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively. However, on a number of occasions, the inhouse development capacity may get prioritized in favor of other products within the company’s portfolio. A product may also be facing competition internally from other projects, not necessarily similar compounds, but perhaps programs better aligned to the overall R&D activities.  (MORE)
Understanding the Global Pharmaceutical Market Understanding the Global Pharmaceutical Market

Although the origins of the modern pharmaceutical industry can be traced back to the late nineteenth century, the real development started only in 1960s due to some significant new discoveries with permanent patent protection.  (MORE)
 

Return policy: We do accept hard copy books if a reason is included. Electronic products including
CD-ROMs and PDF files are non-returnable/non-refundable due to the duplicable nature of these products.

To market your reports, contact us at 800-304-0345 or email
Helpdesk AT PharmaReports DOT com